Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy

Lucid Capital Markets upgraded INmune Bio (INMB) to Buy from Neutral with a $9.00 price target while shares trade at $1.28, down 84% over the past year, implying substantial upside from current levels. The firm incorporated value from CORDStrom (RDEB) and XPro (Alzheimer’s) into its valuation after KOL feedback and new data; INmune will present MissionEB Phase III data on Feb 26. Operational progress includes three commercial pilot manufacturing runs at CGT Catapult and planned regulatory filings: UK MAA by mid-summer 2026 and a U.S. BLA later in 2026. InvestingPro flags rapid cash burn but notes cash > debt and liquid assets > short-term obligations.

Analysis

This is a classic binary small‑cap biotech situation: pipeline optionality dominates valuation while manufacturing and regulatory execution determine whether that optionality crystallizes or evaporates. If clinical/regulatory milestones land as hoped, expect a rapid re‑rating driven less by incremental revenue and more by de‑risking of commercialization (trading multiple expansion versus nearest peers). Conversely, a safety signal, pivotal miss, or CMC setback would compress price into downside dominated by financing risk and potential dilution within 12–18 months.

Second‑order beneficiaries and losers matter here. Third‑party CDMOs, viral/plasmid suppliers and specialty logistics providers gain pricing power and will see shorter lead times become a competitive moat for the issuer; payors and hospitals — currently managing topical care budgets — will be the bottleneck on uptake and pricing, not clinicians. Competing small players with topical‑only approaches stand to lose negotiating leverage and may be forced into discounted partnerships or M&A at lower valuations.

Primary near‑term catalysts are operational (manufacturing scale, CMC stability) and regulatory (pathway clarity and submission windows); these are sequenced and predictable enough that conditional option structures can extract asymmetric payoffs. Volatility will spike around each milestone; implied vol tends to be overpriced vs realized on clean positive readouts but catastrophically punitive on adverse outcomes. Time horizons: trade tactically into the next 3–12 months for readouts and hold longer dated optionality for commercialization outcomes over 12–36 months.

Contrarian take: the market is likely under‑pricing the value of demonstrated third‑party manufacturing runs because it treats CMC as binary capex risk rather than a scalable margin improvement — successful scale reduces go‑to‑market capex and shortens payer contracting timelines, which can multiply NPV by 2–4x even without blockbuster uptake. That said, consensus underestimates payor pushback and will mark down value quickly if clinical effect size, durability, or safety are ambiguous.

Key Decisions for Investors

• Tactical asymmetric long: Establish a size‑limited long via long-dated calls (e.g., Jan‑2028 LEAP calls with a strike in the $4–$6 range) representing ~0.5% fund NAV. Rationale: limited capital at risk, 3–5x payoff on successful regulatory/commercial execution; downside = 100% premium lost if readouts fail.
• Hedge/paired trade: For a cleaner directional play, pair a 0.5% long equity position with a short position in XBI (SPDR Biotech ETF) of equal dollar notional for 3–6 months. Rationale: isolates company‑specific binary risk while neutralizing sector volatility; expected asymmetric payoff if issuer achieves de‑risking milestones.
• Protective equity leg: If taking outright shares, buy near‑dated puts (3–6 month) at ~30–40% OTM to limit dilution/clinical risk over the next financing window. Cost vs reward: pay ~5–10% of position value to cap tail losses that otherwise force liquidation/dramatic dilution.
• Event‑funded spread: Sell shorter‑dated OTM calls against LEAPs or long stock to fund premium if implied vol for near milestones is elevated. Rationale: monetizes high near‑term IV, converting costly calendar decay into a lower net premium while retaining long upside; risk = assignment or capping upside if a large gap up occurs.
• Risk management: Size cumulative exposure to this single issuer at no more than 1–2% of total fund NAV and set hard stop/exit triggers: adverse pivotal safety signal, failed CMC confirmation, or a financing that dilutes >25% at below prior round — each should trigger a reassessment or exit.